1-7 of 7
Naiyer Rizvi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer Rizvi, Ronald Natale, Deborah K. Armstrong, Michael Birrer, Lawrence Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, Denison Kuruvilla, Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed Dar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2749–2757.
https://doi.org/10.1158/1078-0432.CCR-17-1775
Published: 14 June 2018
View article titled, Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Open the PDF for Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer Rizvi, Lisa Malburg, Vicki Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi-Yuan Wu, Agnes Ang, Abdel-Baset Halim, Robert A. Beckman, Darrin Beaupre, Jordan Berlin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3078–3087.
https://doi.org/10.1158/1078-0432.CCR-12-3051
Published: 30 May 2013
View article titled, Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer Rizvi, Raya Khanin, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6599–6608.
https://doi.org/10.1158/1078-0432.CCR-12-0838
Published: 16 December 2012
View article titled, Identification of <em>KIF5B-RET</em> and <em>GOPC-ROS1</em> Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
Open the PDF for Identification of <em>KIF5B-RET</em> and <em>GOPC-ROS1</em> Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions in another window
Includes: Supplementary data
Journal Articles

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Gregory J. Riely, William Pao, DuyKhanh Pham, Allan R. Li, Naiyer Rizvi, Ennapadam S. Venkatraman, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi, Vincent A. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 839–844.
https://doi.org/10.1158/1078-0432.CCR-05-1846
Published: 07 February 2006
View article titled, Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Open the PDF for Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Squalamine, a Novel Antiangiogenic Agent, in Patients with Advanced Cancers

Pankaj Bhargava, John L. Marshall, William Dahut, Naiyer Rizvi, Nina Trocky, Jon I. Williams, Howard Hait, Sharon Song, Kenneth J. Holroyd, Michael J. Hawkins
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 3912–3919.
Published: 01 December 2001
View article titled, A Phase I and Pharmacokinetic Study of Squalamine, a Novel Antiangiogenic Agent, in Patients with Advanced Cancers
Open the PDF for A Phase I and Pharmacokinetic Study of Squalamine, a Novel Antiangiogenic Agent, in Patients with Advanced Cancers in another window
Journal Articles

A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors

Helen X. Chen, John L. Marshall, Elizabeth Ness, R. Russell Martin, Barry Dvorchik, Naiyer Rizvi, Judith Marquis, Margo McKinlay, William Dahut, Michael J. Hawkins
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1259–1266.
Published: 01 April 2000
View article titled, A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors
Open the PDF for A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors in another window
Journal Articles

A Phase I and Pharmacokinetic Study of TNP-470 Administered Weekly to Patients with Advanced Cancer

Pankaj Bhargava, John L. Marshall, Naiyer Rizvi, William Dahut, Joseph Yoe, Manuela Figuera, Kim Phipps, Voon S. Ong, Allen Kato, Michael J. Hawkins
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 1989–1995.
Published: 01 August 1999
View article titled, A Phase I and Pharmacokinetic Study of TNP-470 Administered Weekly to Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacokinetic Study of TNP-470 Administered Weekly to Patients with Advanced Cancer in another window